Transaction overview
MIMEDX Group, headquartered in Marietta, Georgia, acquired Sanara MedTech on July 29, 2026 for $350 million. The deal represents MIMEDX's strategic move to expand its portfolio of regenerative products tailored for surgical markets. Sanara MedTech, based in Fort Worth, Texas, specializes in developing and commercializing advanced biomaterials and cellular therapies designed to support tissue repair and regeneration.
Deal structure and financing
The acquisition was structured as a full equity purchase with no specific details provided on debt financing or leverage metrics. Centerview served as the financial advisor for MIMEDX Group while Truist Securities advised Sanara MedTech. Greenberg Traurig acted as legal counsel to MIMEDX, and Alston & Bird represented Sanara MedTech throughout the transaction.
No lock-up periods were announced by either party at the close of the deal. The terms did not mention any IPO optionality for Sanara MedTech post-acquisition. No seller-retained equity stake was disclosed as part of this agreement.
Strategic context
MIMEDX Group's acquisition of Sanara MedTech aligns with its broader strategy to enhance and diversify its regenerative product offerings within the surgical market segment. The deal strengthens MIMEDX’s position by adding a portfolio of proprietary technologies that complement its existing suite of medical devices and biologics solutions.
Sanara MedTech, on the other hand, decided to divest in order to focus more closely on core competencies and capitalize on the strategic alignment with MIMEDX Group. The proceeds from this transaction will enable Sanara MedTech to further develop its pipeline and invest in research and development activities that align better with its future growth trajectory.
Regulatory path
The acquisition of Sanara MedTech by MIMEDX Group did not require extensive regulatory scrutiny due to the nature of the healthcare products involved and the limited overlap in market presence. The transaction was reviewed under U.S. antitrust laws, specifically through HSR filing requirements. No significant remedies were required to address competitive concerns within the sector.
The deal is subject to customary closing conditions including clearance from relevant competition authorities but did not face any substantial delays or objections during regulatory review processes.